Ushibi announced the official listing of its innovative drug peserizumab injection in China

Youshibi's innovative drug, ximinijia ®, the only biological preparation approved in China that can be used for the treatment of rheumatoid arthritis in the whole pregnancy if there is a clinical need, is officially listed in China Since the first prescription was issued on November 5, it has brought more optimal treatment scheme for Chinese rheumatoid arthritis patients, especially female patients With the listing of siminga ®, ushibi's business in China has expanded to the field of immune system diseases, opening a new journey of development in China In order to make the innovative therapy serve the right patients faster and more accurately, youshibi and Xinkai pharmaceutical, as partners, will take a new path in the patient-centered ecosystem Shanghai, December 14, 2019 / Meitong news agency / -- global biopharmaceutical company youshibi announced that its innovative drug, ximinijia ® (peserizumab injection), was officially launched in China, and the first prescription was issued on November 5, which began to bring more optimal treatment scheme for Chinese rheumatoid arthritis patients, especially female patients With this innovative drug entering the Chinese market, ushibi has embarked on a new journey of development in China, expanding its business to the field of immune system diseases, and will continue to create value for more patients with the upgraded "China plan" Rheumatoid arthritis is an autoimmune disease with erosive arthritis as its main clinical manifestation There are about 5 million rheumatoid arthritis patients in China, of which women are three times as many as men For women of childbearing age, rheumatoid arthritis not only afflicts them with diseases, but also forces them to postpone or change their family planning Professor Tian Xinping, Secretary of the society of Rheumatology branch of Chinese Medical Association, member of the Standing Committee and Director-General of Rheumatology branch of Chinese Medical Association, and chief physician of Rheumatology and Immunology Department of Peking Union Medical College Hospital, pointed out that "childbirth is a basic right of every woman, but rheumatoid arthritis often makes it difficult for women patients to" feel at ease "before, during and after pregnancy Before and during pregnancy, if the patient does not control the disease well, it will not only weaken the ovulation function and prolong the pregnancy time, but also increase the risk of multiple adverse pregnancy outcomes such as premature delivery, low birth weight of the fetus and preeclampsia In addition, the recurrence rate of rheumatoid arthritis is very high Once relapsed, the condition will be more serious, the patient will be more painful, serious and even can only be paralyzed in bed, it is difficult to feed the child in person It is not only the unmet needs of women of childbearing age, but also an important problem faced by every rheumatology and Immunology doctor to control the disease well and have peace of mind at the same time " Siminja ® (peserizumab injection) is the only PEGylated TNF - α inhibitor without Fc fragment It has a higher affinity for human TNF - α and can achieve rapid onset and lasting remission, and almost no placenta transport Based on the unique molecular structure and positive clinical test results, shiminjia ® has become the only biological preparation approved in China to treat rheumatoid arthritis that can be used in the whole pregnancy if there is clinical need in the manual, bringing new treatment options for Chinese rheumatoid arthritis patients, especially women Professor Li Zhanguo, former chairman of Asia Pacific rheumatology alliance, former chairman of Rheumatology branch of Chinese Medical Association, director of Clinical Immunology Center / rheumatology Immunology Department of Peking University People's Hospital and director of Rheumatology immunology Institute, said: "in recent years, the listing of biological agents has opened a new situation for the treatment of rheumatoid arthritis in China However, the clinical compliance rate of patients in China is still low, and the clinical remission rate of patients after one-year treatment is only 22% Among them, it is particularly urgent to improve the treatment status of women of childbearing age: the existing treatment not only needs to adjust the treatment plan according to the pregnancy process of the patients, but also some patients can not get effective control This clinical treatment gap was effectively filled by the injection of peserizumab Based on the results of clinical trials, peserizumab injection has been recommended by many international authoritative guidelines, such as the European Union Against Rheumatism (EULAR), the British rheumatology society, the British Association of rheumatologists (BSR / bhpr) and the Asia Pacific Association of Rheumatology (April), which can be used for the treatment of rheumatoid arthritis patients in pregnancy and lactation, and will also help Chinese patients The improvement of disease remission rate brings new hope for women of childbearing age " Tacovan tier, global vice president and head of international market, said: "we are honored to introduce siminga ® to China, which has benefited 380000 immune disease patients worldwide, and become an important pillar of the upgraded" China plan "of youshibi At the same time, we are also very happy to work with Xinkai pharmaceutical to provide end-to-end health services for patients in combination with their pain points in the whole process before, during and after diagnosis, and to work together to find a new way in the patient-centered ecosystem and better serve Chinese doctors and patients " At present, China has entered many hospitals and pharmacies in China Patients can be concerned about the patient care and patient education launched by the China Health Promotion Foundation The official account of WeChat public is known for its more information Thanks to China's favorable policy on innovative drugs, in the first half of this year, both a new drug for intractable epilepsy and an innovative drug in the field of immunity were approved to carry out three phase clinical trials in China, synchronized with the world; on December 4, an application for clinical trials of biological products for the treatment of osteoporosis was also approved Therefore, ushibi will comprehensively accelerate the process of new drug listing in China and strive to benefit Chinese patients as soon as possible Meanwhile, the excellent time ratio is also actively working with local partners to explore more Internet plus new ways and possibilities to promote the linkage of the three medicine In November 21st, it announced the signing of the strategic cooperation memorandum with Jingdong health, aiming at improving the whole course experience and quality of life of patients, and making innovation "from global to China, and from China to the world" About youshibi, headquartered in Brussels, Belgium, is a global biopharmaceutical company that focuses on the development of innovative drugs and therapies for severe diseases of the immune system and nervous system At present, youshibi has about 7500 employees around the world, and is active in 40 countries around the world Every year, about 25% of its sales are spent on R & D and innovation With global sales of more than 4.6 billion euros in 2018, it is a European Stock Exchange listed company (UCB) Since its establishment in 1928, innovation and flexibility have always been the hallmark of the best time ratio In the past 90 years, ushibi has taken many bold measures to innovate and surpass itself, and innovation and flexibility will continue to lead the company's future development In the early 1990s, it entered the Chinese market and started business In 1996, ushibi established its first office in China in Shanghai With the acquisition of German Schwarz pharmaceutical company and its production plant in Zhuhai in 2006, and the listing of anti epileptic heavyweight products the next year, ushibi has become a rapidly growing pharmaceutical company in China Today, yushbi China is headquartered in Shanghai, with regional offices in Beijing, Chengdu and Guangzhou The new factory is located in Zhuhai With the joint efforts of employees and the cooperation with partners, ushibi China has made positive contributions to improving the lives of millions of patients Next, ushibi will launch more innovative drugs and solutions for the Chinese market in terms of nervous system, immune system and bone health to benefit more patients Source: youshibi 37